

Tuberculosis Reactivation Risk in Dermatology

Leonardo Pescitelli, Federica Ricceri, and Francesca Prignano

ABSTRACT. The treatment of some dermatological diseases, especially psoriasis, has been revolutionized by the advent of biologic therapies that target various immune cells or cytokines. However, biologic therapies may affect the risk of active tuberculosis (TB). We review the published safety data about TB risk reactivation for biologic agents used in dermatology. According to recent findings, psoriasis itself could represent an independent risk factor for TB; a high prevalence of TB was found in patients with psoriasis (18.0%), even after adjusting for age, work, and other characteristics. Latent TB infection was more common in patients with psoriasis (50%) than in those with inflammatory bowel disease (24.2%). Risk of TB reactivation was also influenced by the type of agent used. Several structural and functional differences among biologic drugs could account for differences in risk of granulomatous infection. Different kinetics of currently available tumor necrosis factor (TNF) antagonists, leading to different TNF bioavailability in granulomatous tissue, may explain differences in TB reactivation among patients treated with biologics. One could argue that etanercept should be the first choice of anti-TNF agent in populations at high risk of TB. Risk of TB reactivation during treatment with other biologics is not yet well defined. (*J Rheumatol Suppl.* 2014 May; 91:65–70; doi:10.3899/jrheum.140104)

Key Indexing Terms:

PSORIASIS

LATENT TUBERCULOSIS INFECTION

BIOLOGIC DRUGS

In recent decades, the risk of latent tuberculosis (TB) reactivation has been the focus of much interest in dermatology, particularly because of the introduction of biologic agents in the treatment of immune-mediated cutaneous disorders such as psoriasis. These agents target various immune cells or cytokines that play key roles in local and systemic inflammation, such as tumor necrosis factor- α (TNF- α), T cells, B cells, and interleukins.

Psoriasis is a chronic inflammatory immune-mediated skin disease affecting 2.5% of the world's population¹. While the pathogenic mechanism is not yet completely understood, the pivotal role played by T helper 1 and T helper 17 cells is clear. Biologic drugs target these key steps in the pathogenesis of disease, and can be classified into 3 main categories: TNF- α inhibitors, T cell inhibitors, and interleukin 12 (IL-12)/IL-23 inhibitors. These immune pathways also appear to be crucial in mounting a host defense against bacterial, fungal, and parasitic infections, as well as intracellular pathogens^{2,3,4}.

TB infection affects almost one-third of the world's population, with 10% of infected people developing active TB in their lifetime⁵ and 90% developing latent TB infection (LTBI), a state in which an immune response to *Mycobacterium tuberculosis* (Mtb) is detected in the

absence of clinical features of active disease. From 5% to 10% of patients with LTBI will develop reactivation and this risk is increased in immunocompromised patients⁶.

An increased risk of infection is related to a general immunomodulatory or immunosuppressive effect and is common to all biologics⁷. The effect of biological therapies on TB risk in dermatology must be initially evaluated against regional differences in exposure to Mtb and the underlying inflammatory disorder treated⁸. Psoriasis could represent an independent risk factor for TB. Psoriatic patients have a high prevalence of TB (18.0%), even adjusting for age, work, and other characteristics⁹. The risk of TB reactivation is also influenced by the type of agent used. Several structural and functional differences among biologic drugs could account for the differences in granulomatous infection risk¹⁰.

We review published safety data about TB risk reactivation for biologic agents used in dermatology, focusing solely on English-language randomized controlled trials and their extension studies. Literature searches were conducted through MEDLINE using the search string (etanercept OR infliximab OR adalimumab OR golimumab OR ustekinumab OR briakinumab OR anakinra OR abatacept OR rituximab) AND (psoriasis OR skin diseases) AND (tuberculosis OR safety OR side effect OR adverse event). The literature review extended to April 31, 2013.

TB Risk and Anti-TNF- α Agents Used in Dermatology

Biologic TNF- α antagonists including infliximab (IFX), etanercept (ETN), adalimumab (ADA), and golimumab (GOL) represent a novel type of highly selective therapy approved by both the US Food and Drug Administration

From the Division of Clinical, Preventive and Oncology Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.

L. Pescitelli, MD; F. Ricceri, MD; F. Prignano, MD, PhD, University of Florence.

Address correspondence to Dr. Prignano, Division of Clinical, Preventive and Oncology Dermatology, Department of Surgery and Translational Medicine, Florence University, Ospedale Piero Palagi, V.le Michelangelo 41, 50125 Florence, Italy. E-mail: francesca.prignano@unifi.it

(FDA) and the European Medicines Agency (EMA) for the treatment of plaque-type psoriasis and/or psoriatic arthritis (PsA). The efficacy of TNF- α -targeting agents in treating psoriasis serves as proof of the crucial role played by TNF- α in its pathogenesis¹¹. The effects of TNF- α are also important in host defenses against Mtb and specifically in the formation and maintenance of granulomas¹². Indeed, TNF- α is essential in suppressing the progression and dissemination of mycobacterial infection by activating macrophages, CD4+ and CD8+ T cells, and controlling intracellular mycobacterial growth^{13,14}. It is unsurprising, therefore, that the use of TNF- α inhibitors has been associated with an increased rate of TB. And because each has its own structure and mechanism of action, these agents may pose variable risks regarding TB reactivation¹⁵. In fact, atypical presentations of TB, such as disseminated and extrapulmonary disease, are common in the setting of treatment with anti-TNF- α therapies^{16,17,18}.

A review of the FDA adverse events database from January 1998 through September 2002 identified 138 cases of TB in patients receiving anti-TNF- α ^{19,20}.

Infliximab. IFX is a murine-human chimeric monoclonal antibody neutralizing both soluble and transmembrane TNF- α . Because of its capability in binding transmembrane TNF- α , IFX causes apoptosis of T cells, monocytes, and other TNF- α -bearing cells (TNF- α -producing cells), leading to a highly increased risk of TB reactivation. IFX could also interfere with immune response by inducing both complement-dependent and antibody-dependent cell-mediated cytotoxicity^{21,22,23}.

Three clinical trials [Study of Psoriasis with Infliximab (REMICADE) Induction Therapy — SPIRIT²⁴; European Infliximab for Psoriasis (REMICADE) Efficacy and Safety Study — EXPRESS²⁵; and Evaluation of Infliximab for Psoriasis in a (REMICADE) Efficacy and Safety Study — EXPRESS II²⁶] evaluated the safety of IFX in moderate-to-severe plaque-psoriasis patients. More than 1400 psoriatic patients were exposed to at least 1 dose of IFX and the safety analysis included data up to 50 weeks. No cases of active TB were observed in the SPIRIT and EXPRESS I studies, whereas there were 2 cases of TB in the IFX group in the EXPRESS II study.

Longterm safety of IFX was also examined in a 78-week phase III study in 54 Japanese patients with moderate to severe plaque psoriasis and PsA. In the 50 patients who received IFX in the study period there was no evidence of LTBI reactivation²⁷. Together, these data indicate that IFX is generally well tolerated up to 78 weeks, with a risk of TB reactivation as a significant consideration in using this drug.

Etanercept. Another approved TNF- α blocker, ETN, is a dimeric, soluble recombinant fusion protein constituted by the extracellular domain of the human p75 TNF receptor and the Fc fragment of human IgG1²¹.

Studies revealed that the risk of TB reactivation induced

by antibody-type drugs is significantly greater than for soluble TNF receptor-type drugs^{19,28,29}. Although it is still debated which drug feature determines a differential risk of TB reactivation, the ability to bind to membrane-associated TNF, even if unable to induce cell death, seems to be fundamental. Compared to IFX, ETN, which binds only to soluble TNF- α , is less frequently associated with LTBI reactivation, likely because it does not induce apoptosis in TNF- α -expressing cells and shows limited cytotoxicity and reduced interference with the immune granulomatous response^{21,30,31}.

The longterm safety profile of ETN up to 48 months was examined in a series of connected trials in patients with moderate to severe plaque psoriasis³². In total, 108 patients completed 48 months of therapy; there were no reported cases of TB or opportunistic infections. In a recent Spanish multicenter prospective study in 444 patients with psoriatic disease who were receiving ETN treatment at a dose of 50 mg twice weekly, there were no cases of TB at the 12-month followup³³.

These data suggest that ETN is generally well tolerated in patients with moderate to severe plaque psoriasis over a 4-year treatment period with few serious infections. Among the TNF antagonists, ETN has been reported to be associated with the lowest incidence of TB and a longer lag time to reactivation of latent TB³⁴.

Adalimumab and golimumab. ADA and GOL are fully human monoclonal antibodies that bind to both the soluble and transmembrane bioactive forms of human TNF- α ; ADA differs from GOL by inducing lysis of human monocytes expressing transmembrane TNF- α in the presence of complement or effector cells^{35,36}. Unlike ADA, in dermatology GOL has been approved by the FDA and EMA only for the treatment of PsA.

Three large randomized clinical trials (Randomized controlled EValuation of adalimumab Every other week in moderate to severe psoriasis trial — REVEAL³⁷, Comparative Study of Humira vs Methotrexate vs Placebo in Psoriasis Patients — CHAMPION³⁸, and BELIEVE³⁹) assessed the safety of ADA in patients with moderate to severe psoriasis. In the REVEAL trial, among the 840 patients who received at least 1 dose of ADA during the 52-week treatment period, 1 case of TB was reported. In a longterm, followup study of REVEAL, in which patients received open-label ADA continuously for 3 years, the adverse event profile was consistent with that of the original REVEAL study⁴⁰.

All 3 approved anti-TNF agents indicated for psoriasis therapy have a black box warning required by the FDA concerning development of serious infections, including TB. All 3 can reactivate TB in patients with psoriatic diseases in the relatively short time of 1 year or less, but the real degree of this risk is difficult to estimate³⁴.

A recent case-control study, not specific for psoriasis,

suggested that the risk of TB attributable to ADA is similar to that of IFX and greater than that of ETN; other studies reinforce these findings, confirming a reduced risk of ETN-associated TB compared with risk associated with TNF- α monoclonal antibodies¹⁰. Moreover, the 3 currently available TNF- α antagonists are associated with different median times to onset of infectious TB complications (IFX, 6 weeks; ADA, 3–8 months; ETN, 11.2 months, GOL not known)^{10,41}.

Regarding patients with psoriatic diseases, there are few postmarketing reports on reactivation of LTBI after initiation of anti-TNF therapy, and the frequency varies across different studies^{42,43,44}. In a Spanish study of 144 patients receiving 3 anti-TNF agents, 29% showed tuberculin skin test conversion after different periods of therapy⁴². In a study from Taiwan on 147 patients receiving ETN, ADA, or both, 11% showed interferon- γ releasing assay (IGRA) conversion after a median period of 24 weeks of exposure⁴³. Likewise, in an Italian study in 50 patients receiving the 3 anti-TNF agents as monotherapy or in combination with methotrexate, 7 (14%) showed IGRA conversion after 1 year⁴⁴. In the same study, 2 cases of IGRA conversion were discovered during an annual examination of anti-TNF therapy maintenance, and 1 case was diagnosed as active pulmonary TB 10 months after starting the biologic agent. A recent survey concerning the evaluation of infectious complications during biologic therapy of psoriasis showed a rate of infection of 12.24%, with only 1 case of pulmonary TB in a patient treated with IFX, out of 988 patients⁴⁵.

TB Risk and T Cell Inhibitors Used in Dermatology

Psoriasis is defined as a T cell-mediated autoimmune disease based on the advanced understanding of its pathogenesis. Because of the primary role that T cells play in this disease, a new class of biologics has been designed to interfere with T cell activation and functions. Currently, alefacept is the only T cell inhibitor drug approved for the treatment of psoriasis. Efalizumab was withdrawn from the market because of the associated risk of progressive multifocal leukoencephalopathy⁴⁶. Two additional T cell modulators are currently being evaluated for their use in psoriasis and PsA⁴⁷.

Alefacept. There have been no reported longterm, randomized, placebo-controlled trials of alefacept in patients with moderate to severe psoriasis, although several clinical trials have assessed its efficacy and safety in short-term followup^{48,49,50}. Adverse events associated with alefacept were mostly infectious in nature, but no case of TB reactivation was reported.

Prolonged, prospective, randomized clinical trials are required to assess the longterm safety of alefacept in patients with moderate to severe psoriasis. It should be noted that alefacept is not licensed for use in Europe.

TB Risk and IL-12/IL-23 Inhibitors Used in Dermatology

A third class of biologics classified as IL-12/IL-23 inhibitors has been developed for treating psoriasis. Currently, ustekinumab is FDA-approved and EMA-approved for treatment of chronic plaque psoriasis⁵¹, whereas briakinumab recently had its approval application withdrawn in the United States and Europe to conduct further analysis and clinical trials⁵².

Ustekinumab. Ustekinumab, a fully human monoclonal antibody directed against the shared p40 subunit of IL-12 and IL-23 cytokines, is a recently approved biologic for the treatment of moderate to severe plaque psoriasis⁵¹.

Studies have demonstrated that both IL-12 and IL-23 play important roles in host protection against bacterial and parasitic infections and intracellular pathogens. In particular it seems that individuals with inborn errors in the IL-12/23-interferon- γ circuit are particularly vulnerable to infections caused by mycobacteria, especially atypical mycobacterial infections as well as Mtb^{53,54}.

Two important clinical trials, intended to determine the safety of ustekinumab, are PHOENIX-1⁵⁵ and PHOENIX-2⁵⁶. Both are large-scale, randomized, placebo-controlled, phase III trials designed to evaluate the efficacy and safety of ustekinumab in patients with moderate to severe plaque psoriasis over a period of 5 years. A third clinical trial, the ACCEPT study, directly compares ustekinumab to ETN⁵⁷. None of these reported cases of TB reactivation.

Cumulative safety data about TB reactivation risk were recently published. No cases of active TB were described among the 167 patients with psoriasis with newly identified LTBI who were treated concomitantly with isoniazid at, or before, the start of ustekinumab treatment. Only 1 asymptomatic patient, who did not receive anti-TB treatment, experienced reactivation of LTBI^{58,59}. This case, however, further supports the critical need to identify and treat patients with LTBI before, or at the time of, initiation of treatment with ustekinumab to minimize the risk of developing active TB.

Briakinumab. Briakinumab is a recombinant fully human IgG1 monoclonal antibody directed against the shared p40 subunit of IL-12 and IL-23. Because of its binding to the aforesaid cytokines, briakinumab causes a decrease in secretion of IL-6, IL-12, interferon- γ , and TNF- α . In a phase II study in 180 patients with psoriatic diseases who were treated with briakinumab, there were no cases of TB reactivation in the longterm safety analysis up to 48 weeks⁶⁰.

Tuberculosis Risk and Other Biologics

Anakinra. Anakinra is a recombinant IL-1 receptor antagonist used primarily to treat rheumatoid arthritis (RA)⁶¹. Although outside FDA-approved indications, anakinra has also been found to be useful in a variety of immune-mediated and autoimmune skin disorders in which traditional therapy has failed or resulted in side effects.

However, the tolerability of anakinra in the treatment of dermatological diseases is not yet clear⁶².

Abatacept. Abatacept is a fusion protein composed of an Fc fragment of IgG1 and the extracellular domain of cytotoxic lymphocyte antigen-4, which inhibits T cell costimulation. Abatacept is currently approved for the treatment of RA⁶³. A phase II study in patients with PsA has terminated and showed that 10 mg/kg may be an effective and safe treatment⁶⁴. No other safety data are available in dermatology.

Rituximab. Rituximab (RTX) is a chimeric human/mouse monoclonal antibody directed at the CD20 antigen expressed on mature B and pre-B cells. It is approved for the treatment of patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, and moderate to severe RA who have had an inadequate response to TNF inhibitors⁶⁵.

In dermatology, RTX is a useful off-label treatment for primary cutaneous B cell lymphoma, pemphigus vulgaris, dermatomyositis, and idiopathic thrombocytopenic purpura, to name a few⁶⁶. The risk of TB associated with RTX is currently unknown. No cases of TB reactivation were observed in clinical trials of RTX used in rheumatology, in which pre-screening for LTBI was not performed^{8,67}.

Regarding the use of RTX in the treatment of dermatological disorders, very few randomized, controlled, clinical trials are available, so guidelines for the off-label use of this medication come from anecdotal case reports and cohort studies. In the majority of patients, RTX is safe and tolerable, with only mild infectious complications, although strict care and guidance should be followed with each patient treated because longterm safety in dermatological conditions has not been firmly established⁶⁸.

The advent of biologics in dermatology has substantially changed the treatment of cutaneous autoimmune inflammatory diseases. However, the fact that these agents involve immunosuppressive activity has raised safety concerns, particularly regarding reactivation of latent infections, most notably that caused by Mtb.

Given the crucial role played by TNF in granuloma formation, the link between drugs directed against this cytokine and predisposition to TB seems obvious. In fact, most cases of TB associated with anti-TNF agents are due to reactivation of LTBI, rather than newly acquired infections. Moreover, atypical presentations of TB such as extrapulmonary and disseminated forms seem to be more common in patients treated with anti-TNF therapy than in those in immunocompetent patients. Most reported cases occurred within 2–4 months after starting anti-TNF therapy, in regions with a low incidence of TB.

Different kinetics of the currently available TNF antagonists, leading to different TNF bioavailability in granulomatous tissue, may explain differences in TB reactivation among patients treated with these biologic drugs. In particular, studies have shown that the soluble TNF receptor

ETN seems to be associated with a lower risk of TB reactivation compared to that associated with monoclonal antibodies IFX and ADA. The explanation of this may reflect the reduced ability of ETN to disrupt granuloma. In fact, ETN is also ineffective in the treatment of chronic granulomatous inflammation in Crohn disease, and potentially less effective in other granulomatous diseases such as sarcoidosis and granulomatosis with polyangiitis⁶⁹. For these reasons, one could argue that ETN should be the first anti-TNF used in populations with a high risk of TB.

The risk of TB reactivation during treatment with other biologics is much less known. There is a relative lack of clinical data on this subject in dermatological diseases, and following the experience with anti-TNF- α , because of the introduction of TB screening before starting biologic therapy. However, biologics directed against targets that are not implicated in host defenses against Mtb, such as anakinra and RTX, seem to have a very lower risk of TB reactivation.

The above report on risk of reactivation of LTBI in dermatology can be summarized as follows:

- Biologic therapies used in dermatology specifically for psoriasis are associated with significant risk to reactivate LTBI
- Psoriasis itself could represent an independent risk factor for TB
- Risk of TB is not the same for the currently available biologic agents

REFERENCES

1. Schäfer T. Epidemiology of psoriasis. Review and the German perspective. *Dermatology* 2006;212:327-37.
2. Schluger NW, Rom WN. The host immune response to tuberculosis. *Am J Respir Crit Care Med* 1998; 157 Pt 1:679-91.
3. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4 T cell responses after vaccination and during Mycobacterium tuberculosis challenge. *Nat Immunol* 2007; 8:369-77.
4. Zenaro E, Donini M, Dusi S. Induction of Th1/Th17 immune response by *Mycobacterium tuberculosis*: role of dectin-1, mannose receptor, and DC-SIGN. *J Leukoc Biol* 2009;86:1393-401.
5. Stop TB Partnership and World Health Organization. 2009 Update Tuberculosis Facts. Geneva: World Health Organization; 2009. [Internet. Accessed February 25, 2014.] Available from: www.who.int/tb/publications/2009/tbfactsheet_2009update_one_page.pdf
6. Vynnycky E, Fine PE. Lifetime risks, incubation period and serial interval of tuberculosis. *Am J Epidemiol* 2000;152:247-63.
7. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. *Cochrane Database Syst Rev* 2011;2:CD008794.
8. De Keyser F. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. *Curr Rheumatol Rev* 2011;7:77-87.
9. Balato N, Di Costanzo L, Ayala F, Balato A, Sanduzzi A, Bocchino M. Psoriatic disease and tuberculosis nowadays. *Clin Dev Immunol* 2012;2012:747204.

10. Wallis S. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. *Lancet Infect Dis* 2008;8:601-11.
11. Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. *Expert Opin Ther Targets* 2008;12:1085-96.
12. Kaplan G, Freedman VH. The role of cytokines in the immune response to tuberculosis. *Res Immunol* 1996;147:565-72.
13. Denis M. Tumor necrosis factor and granulocyte macrophage colony stimulating factor stimulate human macrophages to restrict growth of virulent *Mycobacterium avium* and to kill avirulent *M. avium*: killing effector mechanism depends on the generation of reactive nitrogen intermediates. *J Leukoc Biol* 1991;49:380-7.
14. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. *Cell* 1989; 56:731-40.
15. Ellerin T, Rubin RH, Weinblatt ME. Infections and antitumor necrosis factor alpha therapy. *Arthritis Rheum* 2003;48:3013-22.
16. Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, National Psoriasis Foundation, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. *J Am Acad Dermatol* 2008;59:209-17.
17. Cooper AM, Khader SA. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. *Immunol Rev* 2008;226:191-204.
18. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. *Lancet Infect Dis* 2003;3:148-55.
19. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. *Clin Infect Dis* 2004;39:1254-5.
20. Sivamani RK, Goodarzi H, Garcia MS, Raychaudhuri SP, Wehrli LN, Ono Y, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. *Clin Rev Allergy Immunol* 2012;44:121-40.
21. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor-alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. *Arthritis Rheum* 2008;58:1248-57.
22. Fossati G, Nesbitt AM. Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. *Am J Gastroenterol* 2005;100 Suppl:S298-S299.
23. Fallahi-Sichani M, Flynn JL, Linderman JJ, Kirschner DE. Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. *J Immunol* 2012;188:3169-78.
24. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. *J Am Acad Derm* 2004;51:534-42.
25. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al; for the EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. *Lancet* 2005;366:1367-74.
26. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomised comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-severe plaque psoriasis. *J Am Acad Dermatol* 2007;56:31.e1-15
27. Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. *J Dermatol Sci* 2010;59:40-9.
28. Wallis RS. Infectious complications of tumor necrosis factor blockade. *Curr Opin Infect Dis* 2009;22:403-9.
29. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. *Arthritis Rheum* 2009; 60:1884-94.
30. Plessner HL, Lin PL, Kohno T, Louie JS, Kirschner D, Chan J, et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. *J Infect Dis* 2007;195:1643-50.
31. Nestle FO, Kaplan DH, Barker J. Psoriasis. *N Engl J Med* 2009;361:496-509.
32. Papp KA, Poulin Y, Bissonnette R, Bourcier M, Toth D, Rosoph L, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. *J Am Acad Dermatol* 2012;66:e33-45.
33. Puig L, Camacho Martínez FM, Gimeno Carpio E, López-Ávila A, García-Calvo C. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in : results of a multicentric prospective study at 12 months follow-up. *Dermatology* 2012;225:220-30.
34. Wallis RS. Biologics and infections: lessons from tumor necrosis factor blocking agents. *Infect Dis Clin North Am* 2011;25:895-910.
35. Shealy D, Cai A, Staquet K, Baker A, Lacy ER, Johns L, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. *MAbs* 2010; 2:428-39.
36. Shen C, Van Assche G, Rutgeerts P, Ceuppens JL. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. *Inflamm Bowel Dis* 2006;12:22-8.
37. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. *J Am Acad Dermatol* 2008;58:106-15.
38. Saurat JH, Stiogl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). *Br J Dermatol* 2008;158:558-66.
39. Thaci D, Ortonne JP, Chimenti S, Ghislain PD, Arenberger P, Kragballe K, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. *Br J Dermatol* 2010;163:402-11.
40. Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. *J Am Acad Dermatol* 2012;66:241-51.
41. Bieber J, Kavanaugh A. Tuberculosis and opportunistic infections: relevance to biologic agents. *Clin Exp Rheumatol* 2004;22:126-33.
42. Sanchez-Moya AI, Dauden E. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. *J Eur Acad Dermatol Venereol* 2011;25:730-3.
43. Garcovich S, Ruggeri A, D'Agostino M, Ardito F, De Simone C, Delogu G, et al. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha

- treatment: a prospective, observational study. *J Eur Acad Dermatol Venereol* 2012;26:1572-6.
44. Chiu HY, Hsueh PR, Tsai TF. Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. *Br J Dermatol* 2011;164:553-9.
 45. Sanchez-Regana M, Dilme E, Puig L, Bordas X, Carrascosa JM, Ferran M, et al. Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group. *Actas Dermo-Sifiliograficas* 2010;101:156-63.
 46. Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Dal Pan G. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. *J Am Acad Dermatol* 2011;65:546-51.
 47. Laws PM, Young HS. Current and emerging systemic treatment strategies for psoriasis. *Drugs* 2012;72:1867-80.
 48. Shah A, O'Neill J, Feldman SR. Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series. *J Drugs Dermatol* 2010;9:1491-4.
 49. Roberts JL, Ortonne J-P, Jerry KL, Korman N, Van De Kerkhof P. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis. *J Am Acad Dermatol* 2010;62:968-78.
 50. Krueger GG, Gottlieb AB, Sterry W, Korman N, Van De Kerkhof P. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. *J Dermatolog Treat* 2008;19:146-55.
 51. Centocor Ortho Biotech Inc. (2009). Stelara medication label. [Internet. Accessed February 19, 2014.] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/1252611bl.pdf
 52. Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. *Am J Clin Dermatol* 2011;12:113-25.
 53. D'Elios MM, Del Prete G, Amedei A. Targeting IL-23 in human diseases. *Expert Opin Ther Targets* 2010;14:759-74.
 54. Filipe-Santos O, Bustamante J, Chappier A, Vogt G, de Beaucoudrey L, Feinberg J, et al. Inborn errors of IL-12/23- and IFN- γ -mediated immunity: molecular, cellular, and clinical features. *Semin Immunol* 2006;18:347-61.
 55. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet* 2008;371:1665-74.
 56. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). *Lancet* 2008;371:1675-84.
 57. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. *N Engl J Med* 2010;362:118-28.
 58. Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, et al. PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. *Br J Dermatol* 2012;167:1145-52.
 59. Tsai T-F, Chiu H-Y, Song M, Chan D. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the trial. *Br J Dermatol* 2013;168:444-6.
 60. Kimball AB, Zhong J, Valdes JM, Gordon K. Retreatment efficacy and long-term safety of the fully human, interleukin-12/23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48 week results from a phase II trial to severe psoriasis: 48 week results from a phase II trial [abstract]. 67th Meeting of the American Academy of Dermatology, San Francisco, March 6-10, 2009. *J Am Acad Dermatol* 2009;60:Ab.168.
 61. Kineret 100 mg solution for injection. Summary of product characteristics. Stockholm: Biowitrum AB; 2009.
 62. Belloni B. Novel immunological approaches in the treatment of atopic eczema. *Curr Opin Allergy Clin Immunol* 2008;8:423-7.
 63. Bristol-Myers Squibb. (August, 2009). Orencia package insert May 28, 2011 [revised December 2013]. [Internet. Accessed February 19, 2014.] Available from: http://packageinserts.bms.com/pi/pi_orencia.pdf
 64. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. *Arthritis Rheum* 2011;63:939-48.
 65. Genentech USA Inc. (April 2011). Rituxan package insert, May 28, 2011 [revised September 2013]. [Internet. Accessed February 19, 2014.] Available from: <http://www.genentech.com/gene/products/information/pdf/rituxan-prescribing.pdf>
 66. Scheinfeld N. A review of rituximab in cutaneous medicine. *Dermatol Online J* 2006;12:3.
 67. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. *Rheumatology* 2012;51 Suppl 5:v38-47.
 68. Jason JM, Wolinsky C. Rituximab. A review of dermatological applications. *J Clin Aesth Dermatol* 2009;2:29-37.
 69. Thalayasingam N, Isaacs JD. Anti-TNF therapy. *Best Pract Res Clin Rheumatol* 2011;25:549-67.